<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02265718</url>
  </required_header>
  <id_info>
    <org_study_id>A9001489</org_study_id>
    <nct_id>NCT02265718</nct_id>
  </id_info>
  <brief_title>A Study To Evaluate The Difference In iPad-Based Cognitive Video Game (Akili Interactive's Project: EVO) Performance In Amyloid-Positive Versus Amyloid-Negative Healthy Elderly Volunteers</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Controlled Trial To Study Difference In Cognitive Learning Associated With Repeated Self-administration Of Remote Computer Tablet-based Application Assessing Dual-task Performance Based On Amyloid Status In Healthy Elderly Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the difference in learning and performance measures
      associated with repeated use of an iPad video game (Akili Interactive's Project: EVO) in
      healthy elderly volunteers based on amyloid status.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>divided attention performance</measure>
    <time_frame>Day 0 - Day 28</time_frame>
    <description>The difference in effect of cognitive training on divided attention performance as measured by teh pre/post training change in interference cost on EVO dueal task assessment at Day 28.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>sustained attention, impulsivity and episodic memory</measure>
    <time_frame>Day 0 - Day 28</time_frame>
    <description>The difference in effect of cognitive training on sustained attention, impulsivity and episodic memory as measured by the pre/post training change in performance at day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>perforamce on EVO dual task assessment, TOVA and RAVLT</measure>
    <time_frame>Day 0 - Day 28</time_frame>
    <description>The performance on EVO dual task assessment, Test of Variables of Attention (TOVA and Rey Auditory Verbal Learning Test (RAVLT) as measured by the pre and post training scores at Day 0 and Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>within subject change on EVO, TOVA and RAVLT</measure>
    <time_frame>Day 0 - Day 28</time_frame>
    <description>The within subject change on EVO dual task assessment, TOVA and RAVLT between day -28 and Day 0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>(Amyloid Negative)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Amyloid Positive</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritalin</intervention_name>
    <description>1 - 20 mg tablet taken once on Day 0 and taken once on Day 28</description>
    <arm_group_label>(Amyloid Negative)</arm_group_label>
    <other_name>methylphenidate hydrochloride 20mg tablet taken once on day 0 and once on day 28</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 - matching tablet taken once on Day 0 and once on Day 28</description>
    <arm_group_label>(Amyloid Negative)</arm_group_label>
    <other_name>matched placebo tablet taken once on day 0 and once on day 28</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritalin</intervention_name>
    <description>1 - 20 mg tablet taken once on Day 0 and taken once on Day 28</description>
    <arm_group_label>Amyloid Positive</arm_group_label>
    <other_name>methylphenidate hydrochloride 20mg tablet taken once on day 0 and once on day 28</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 - matching tablet taken once on Day 0 and once on Day 28</description>
    <arm_group_label>Amyloid Positive</arm_group_label>
    <other_name>matched placebo tablet taken once on day 0 and once on day 28</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males and females between the ages of 70 and 80.

          -  Subjects must have BMI of 17.5 to 32 kg/m2 and total body weight &gt; 110 pounds.

          -  Acceptable screening MRI and PET scans that pass quality control requirements.

        Exclusion Criteria:

          -  Co-morbid diagnosis of clinically documented Alzheimer's disease; - Significant
             cognitive impairment;

          -  MMSE (mini mental state examination) score &lt;26
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, LLC</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broward Research Group</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jasper Clinic, Inc.</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A9001489&amp;StudyName=A%20Study%20To%20Evaluate%20The%20Difference%20In%20iPad-Based%20Cognitive%20Video%20Game%20%28Akili%20Interactive%27s%20Project%3A%20EVO%29%20Performance%20In%20Amyloid-Posi</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2014</study_first_submitted>
  <study_first_submitted_qc>October 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2014</study_first_posted>
  <last_update_submitted>July 25, 2016</last_update_submitted>
  <last_update_submitted_qc>July 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>elderly volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

